Theravance Biopharma Ownership
| TBPH Stock | USD 8.53 0.09 1.04% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 49.4 M | Current Value 48.3 M | Avarage Shares Outstanding 51.4 M | Quarterly Volatility 13.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Theravance |
Theravance Stock Ownership Analysis
About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of Theravance Biopharma was at this time reported as 4.22. The company recorded a loss per share of 0.89. Theravance Biopharma had not issued any dividends in recent years. Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. Theravance Bio is traded on NASDAQ Exchange in the United States. To find out more about Theravance Biopharma contact Rick MBA at 650 808 6000 or learn more at https://www.theravance.com.Besides selling stocks to institutional investors, Theravance Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Theravance Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Theravance Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Theravance Biopharma Quarterly Liabilities And Stockholders Equity |
|
Theravance Biopharma Insider Trades History
About 15.0% of Theravance Biopharma are currently held by insiders. Unlike Theravance Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Theravance Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Theravance Biopharma's insider trades
Theravance Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Theravance Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Theravance Biopharma backward and forwards among themselves. Theravance Biopharma's institutional investor refers to the entity that pools money to purchase Theravance Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-03-31 | 967.5 K | Park West Asset Management Llc | 2023-12-31 | 900 K | D. E. Shaw & Co Lp | 2024-03-31 | 781.6 K | Jacobs Levy Equity Management, Inc. | 2024-03-31 | 558 K | Bank Of America Corp | 2024-03-31 | 520.5 K | Northern Trust Corp | 2024-03-31 | 488.8 K | Morgan Stanley - Brokerage Accounts | 2024-03-31 | 419.1 K | Jane Street Group, Llc | 2023-12-31 | 371.5 K | Wellington Management Company Llp | 2024-03-31 | 331 K | Weiss Asset Management Lp | 2023-12-31 | 7.5 M | Madison Avenue Partners, Lp | 2024-03-31 | 7 M |
Theravance Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theravance Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theravance Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theravance Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Theravance Biopharma Corporate Filings
F4 | 22nd of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 15th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 13th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of April 2024 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Theravance Stock
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 1.191 | Quarterly Revenue Growth 0.392 | Return On Assets (0.06) | Return On Equity (0.16) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.